How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/advanced-her2positive-gastric-or-gastroesophageal-junction-gej-adenocarcinoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Enhertu	trastuzumab-deruxtecan	Daiichi Sankyo		Receptor tyrosine-protein kinase erbB-2		2019-01-01
Enhertu	Enhertu	Washington D.C. Veterans Affairs Medical Center		DNA topoisomerase 1, Receptor tyrosine-protein kinase erbB-2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Daiichi Sankyo · 1 drug in Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
Washington D.C. Veterans Affairs Medical Center · 1 drug in Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma:

Cite this brief

Drug Landscape (2026). Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/advanced-her2positive-gastric-or-gastroesophageal-junction-gej-adenocarcinoma. Accessed 2026-06-10.

Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing